291 related articles for article (PubMed ID: 29937336)
21. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients.
Julka PK; Sharma DN; Mallick S; Gandhi AK; Joshi N; Rath GK
J Cancer Res Ther; 2013; 9(3):381-6. PubMed ID: 24125970
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
23. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
De Sanctis V; Mazzarella G; Osti MF; Valeriani M; Alfó M; Salvati M; Banelli E; Tombolini V; Enrici RM
Anticancer Drugs; 2006 Sep; 17(8):969-75. PubMed ID: 16940807
[TBL] [Abstract][Full Text] [Related]
27. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
[TBL] [Abstract][Full Text] [Related]
28. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide.
Fiorica F; Berretta M; Colosimo C; Stefanelli A; Ursino S; Zanet E; Palmucci T; Maugeri D; Malaguarnera M; Palmucci S; Grasso M; Tirelli U; Cartei F
Arch Gerontol Geriatr; 2010; 51(1):31-5. PubMed ID: 19628288
[TBL] [Abstract][Full Text] [Related]
29. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
30. Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
O'Leary B; Mandeville HC; Fersht N; Solda F; Mycroft J; Zacharoulis S; Vaidya S; Saran F
J Neurooncol; 2016 Apr; 127(2):295-302. PubMed ID: 26842817
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
32. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R
J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965
[TBL] [Abstract][Full Text] [Related]
35. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
37. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
[TBL] [Abstract][Full Text] [Related]
39. Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Skardelly M; Dangel E; Gohde J; Noell S; Behling F; Lepski G; Borchers C; Koch M; Schittenhelm J; Bisdas S; Naumann A; Paulsen F; Zips D; von Hehn U; Ritz R; Tatagiba MS; Tabatabai G
Oncologist; 2017 May; 22(5):570-575. PubMed ID: 28360216
[TBL] [Abstract][Full Text] [Related]
40. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]